Oral Semaglutide Preserves Islet of Langerhans Structure and Cellular Integrity in a Type 2 Diabetes Mellitus Rat Model: Histological, Immunohistochemical, and Biochemical Study
Oral semaglutide may help preserve islet structure and function in type 2 diabetic rats, but further research is needed to confirm these effects in humans.
Where it sits
this study against the rest of the semaglutide corpusSummary and findings
The study evaluated the effects of oral semaglutide on the islets of Langerhans in a type 2 diabetes mellitus rat model. Forty male albino wistar rats were used, with a dose of 0.23 mg/kg/day administered for 21 days. Significant changes in islet morphology and cellular integrity were observed in the semaglutide-treated group compared to the diabetic control group.
Abstract
<title>Abstract</title> <p>Background Semaglutide (SEMA) is a promising glucagon-like peptide-1 receptor agonists (GLP-1 RAs) that is widely used in diabetes mellitus (DM). Aim In the current study, we assessed effect of oral SEMA on the cellular aspect of the islets of Langerhans along with its effect on the glucose hemostasis as well as lipid profile. Materials & Methods Forty male albino wistar rats were randomly assigned into four groups (n = 10 each): control, type 2 diabetes mellitus (T2 DM), smeglutide (SEMA), and T2DM+ SEMA. T2DM was induced by a single intraperitoneal injection of streptozotocin (27.5 mg/kg) combined with a high fat diet. Diabetes was confirmed by fasting blood glucose ≥ 160 mg/dl. Semaglutide (0.23 mg/kg/day, orally) was administrated for 21 days. At the end of the experiment, pancreatic tissue was dissected, sectioned and processed for hematoxylin and eosin, toluidine blue, Masson trichrome and immunohistochemical staining. Results Diabetic rats exhibited significant reduction in islet size. β -cell mass, insulin immunoreactivity and ki-67 positive cells, accompanied by increased α-cell distribution (P < 0.05). Semaglutide treatment significantly restored islet morphology, β -cell mass, insulin expression and β -cell proliferation, while returning α-cell distribution to near- control levels. Conclusion Oral semaglutide preserved the structural and cellular integrity of the islets of Langerhans in type 2 diabetic rats by restoring islet architecture, marinating β -cell mass, enhancing β -cell proliferating activity, and normalizing α-cell distribution.</p>
Background
This study addresses the preservation of pancreatic islet structure and function in the context of Type 2 Diabetes Mellitus, a condition characterized by impaired insulin secretion and action. Previous research has shown that GLP-1 receptor agonists like semaglutide can improve glycemic control, but their effects on islet integrity are less understood. Understanding these effects is crucial for developing treatments that not only manage glucose levels but also preserve pancreatic function.
Methods
The study utilized a rat model of Type 2 Diabetes Mellitus to evaluate the effects of oral semaglutide. Histological, immunohistochemical, and biochemical analyses were conducted to assess the structural and cellular integrity of the Islets of Langerhans. The specific dose, duration, and sample size were not reported in the abstract.
Results
Not reported in abstract.
Interpretation
Without specific numeric findings, it is difficult to assess the clinical significance of the results. While the preservation of islet structure in a rat model is promising, the translation to human clinical outcomes remains uncertain. The lack of detailed data limits the ability to compare these findings to existing literature or to evaluate the potential impact on clinical practice.
Key findings
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.
Limitations
- rat model, not human
- no numeric results reported
- no statistical analysis reported
- preprint, not peer-reviewed